Latest Commercialization News

EQ Resources has successfully commissioned a third XRT ore sorter at its Saloro tungsten operation, increasing sorting capacity by 50% and improving processing efficiency. An updated ore reserve estimate is expected in early Q4 2025, reflecting operational gains and stronger tungsten prices.

Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.

RPM Automotive Group Ltd reported steady FY25 results with improved margins despite a slight revenue dip, while outlining strategic growth and tyre recycling expansion plans for FY26.

RAS Technology Holdings reports a robust 31% revenue increase in FY25, marking its second consecutive profitable year, driven by strategic acquisitions and global partnerships that position it for sustained growth.

dorsaVi appoints Mathew Regan as Group CEO to spearhead commercialisation of next-gen RRAM-enabled AI and robotics technologies, aiming for global expansion.

Cosmos Exploration’s optioned entity, EAU Lithium, has agreed to acquire a fully constructed pilot plant from Vulcan Energy Resources to advance lithium extraction testing in Bolivia. This move strengthens Cosmos’ strategic foothold in one of the world’s most promising lithium regions.

SomnoMed delivered a strong FY25 performance with revenue climbing 22% to $111.5 million and EBITDA turning positive at $9.2 million, boosted by operational improvements and FDA clearance of its Rest Assure device. The company projects further growth in FY26 with expanded manufacturing and ongoing innovation.

Control Bionics Limited has announced a $2.06 million non-renounceable rights issue to fund the commercial expansion of its NeuroStrip device and bolster NeuroNode operations. The capital raise is underwritten to approximately $1.15 million by major shareholders and strategic partners.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

Zoono Group Limited reported a 19.1% revenue increase to NZ$1.25 million for FY2025, alongside a significantly reduced net loss. The company is pivoting towards B2B markets, focusing on antimicrobial and shelf-life extension technologies, supported by a recent AUD 1.78 million capital raise.

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

Lynas Rare Earths reported FY25 results featuring record NdPr output and the first commercial heavy rare earths production outside China, alongside a $750 million equity raise to fund its ambitious Towards 2030 growth strategy.